2016
Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation
Krezdorn N, Murakami N, Pomahac B, Riella L. Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation. American Journal Of Transplantation 2016, 16: 3305-3307. PMID: 27457067, PMCID: PMC5087655, DOI: 10.1111/ajt.13977.Peer-Reviewed Original Research
2014
The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant
Chandraker A, Arscott R, Murphy G, Lian C, Bueno E, Marty F, Rennke H, Milford E, Tullius S, Pomahac B. The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant. American Journal Of Transplantation 2014, 14: 1446-1452. PMID: 24797454, DOI: 10.1111/ajt.12715.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsFacial TransplantationFemaleGraft RejectionHumansImmunity, CellularMiddle AgedConceptsAntibody-mediated rejectionPostoperative day 5Management of AMRDonor-specific antibody titersSubsequent antibody-mediated rejectionGrade III rejectionStandard induction regimenAnti-HLA antibodiesExtensive chemical burnsComposite tissue allotransplantationFull face transplantationMechanism of actionPreoperative crossmatchPresensitized recipientsSensitized recipientsDSA levelsInduction regimenC4d depositsPositive donorsBanff classificationAntibody titersCombination therapyPoor functionHistological signsClinical signs